Cardiac hormones target nuclear oncogenes c-Fos and c-Jun in carcinoma cells

European Journal of Clinical Investigation

Volumn 43, Issue 11, 2013, Pages 1156-1162

  Manimala, Neil J ^a   Frost, Chelsea D ^a   Lane, Meghan L ^a   Higuera, Mariana ^a   Beg, Rana ^a   Vesely, David L ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Atrial natriuretic peptide; C Fos; C Jun; Kaliuretic peptide; Long acting natriuretic peptide; Vessel dilator

Indexed keywords

HORMONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ATRIAL NATRIURETIC FACTOR; ATRIAL NATRIURETIC FACTOR PRECURSOR (79-98); ATRIAL NATRIURETIC FACTOR PROHORMONE (1-30), HUMAN; ATRIAL NATRIURETIC FACTOR PROHORMONE (31-67); PEPTIDE FRAGMENT; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE INHIBITOR; PROTEIN PRECURSOR;

ARTICLE; CARCINOMA CELL; CELL NUCLEUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG SMALL CELL CANCER; ONCOGENE C FOS; ONCOGENE C JUN; PRIORITY JOURNAL; PROTO ONCOGENE; VESSEL DILATOR; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; ATRIAL NATRIURETIC FACTOR; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; NEOPLASMS; PEPTIDE FRAGMENTS; PROTEIN KINASE INHIBITORS; PROTEIN PRECURSORS; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN;

EID: 84885428655     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12153     Document Type: Article

References (34)

1. Muller R, Bravo R, Burckhardt J, Curran T. Induction of c-Fos gene and protein by growth factors precedes activation of c-myc. Nature 1984;312:716-20.
2. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-400.
3. Sagar S, Edwards R, Sharp F. Epidermal growth factor and transforming growth factor α induce c-Fos gene expression in retinal Muller cells in vivo. J Neurosci Res 1991;29:549-59.
4. Guller M, Toualbi-Abed K, Legand A, Michel L, Mauviel A, Bemuau D et al. c-Fos overexpression increases the proliferation of human hepatocytes by stabilizing nuclear Cyclin-D1. World J Gastroenterol 2008;14:6339-46.
5. Arbuthnot P, Kew M, Fitschen W. c-Fos and c-Myc oncoprotein expression in human hepatocellular carcinomas. Anticancer Res 1991;11:921-4.
6. Borlak J, Meier T, Halter R, Spanel R, Spanel-Borowski K. Epidermal growth factor-induced hepatocellular carcinoma: gene expression profiles in precursor lesions, early stage and solitary tumours. Oncogene 2005;24:1809-19.
7. Yuen MF, Wu PC, Lau JYN, Lai CL. Expression of c-Myc, c-Fos and c-Jun in hepatocellular carcinoma. Cancer 2001;91:106-12.
8. Halazonetis TD, Georgopoulos K, Greenberg ME, Leder P. c-Jun dimerizes with itself and c-Fos, forming complexes of different DNA binding proteins. Cell 1988;55:917-24.
9. Rauscher F, Cohen D, Curran T, Bos T, Vogt P, Bohmann D et al. Fos-associated protein p39 is the product of the jun proto-oncogene. Science 1988;240:1010-6.
10. Monje P, Hernandez-Losa J, Lyons RJ, Castellone MD, Gutkind JS. Regulation of the transcriptional activity of c-Fos by ERK. A novel role for the prolyl isomerase PIN1. J Biol Chem 2005;280:35081-4.
11. Feng DY, Zheng H, Tan Y, Cheng RX. Effect of phosphorylation of MAPK and STAT-3 and expression of c-Fos and c-Jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol 2001;7:33-6.
12. Sun Y, Eichelbaum EJ, Lenz A, Wang H, Vesely DL. Epidermal growth factor's activation of Ras is inhibited by four cardiac hormones. Eur J Clin Invest 2010;40:408-13.
13. Derijard B, Hibi M, Wu IH, Barrett T, Su B, Deng T et al. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 1994;76:1025-37.
14. Zhang X, Wrzeszczynska MH, Horvath CM, Darnell JE. Interacting regions in STAT-3 and c-Jun that participate in cooperative transcriptional activation. Mol Cell Biol 1999;19:7138-46.
15. Vesely DL. New anticancer agents: hormones made within the heart. Anticancer Res 2012;32:2515-22.
16. Vesely DL. Natriuretic hormones. In: Alpern RJ, Moe OW, Caplan M, editors. Seldin and Geibisch's The Kidney: Physiology and Pathology, 5th Edn. London, UK: Elsevier Inc; 2013: pp 1241-81.
17. Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr, Vesely DL. Cardiac hormones and urodilatin eliminate up to 86% of human small-cell lung carcinomas in mice. Eur J Clin Invest 2008;38:562-70.
18. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL et al. Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 2007;21:445-52.
19. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr. Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo 2007;21:973-8.
20. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 2006;26:3217-22.
21. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 2006;26:4143-8.
22. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Insulin and epidermal growth factor activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. J Cancer Mol 2007;3:113-20.
23. Sun Y, Eichelbaum EJ, Skelton WP IV, Lenz A, Regales N, Wang H et al. Vessel dilator and kaliuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009;29:971-5.
24. Sun Y, Eichelbaum EJ, Lenz A, Skelton WP IV, Wang H, Vesely DL. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells. Anticancer Res 2009;29:1889-93.
25. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007;27:1387-92.
26. Sun Y, Eichelbaum EJ, Wang H, Vesely DL. Atrial natriuretic peptide and long-acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 2007;27:3813-8.
27. Lane ML, Frost CD, Nguyen JP, Skelton WP IV, Skelton M, Vesely DL. Potent selective inhibition of STAT-3 versus STAT-1 by cardiac hormones. Mol Cell Biochem 2012;371:209-15.
28. Lane ML, Santana O, Frost CD, Nguyen J, Guerrero J, Skelton WP IV et al. Cardiac hormones are c-Jun-N-terminal kinase 2-inhibiting peptides. Anticancer Res 2012;32:721-6.
29. Saba SR, Garces AH, Clark LC, Soto J, Gower WR Jr, Vesely DL. Immunocytochemical localization of atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide in human pancreatic adenocarcinomas. J Histochem Cytochem 2005;53:989-95.
30. Saba SR, Vesely DL. Cardiac natriuretic peptides: hormones with anticancer effects that localize to nucleus, cytoplasm, endothelium and fibroblasts of human cancers. Histol Histopathol 2006;21:775-83.
31. Winters CJ, Sallman AL, Baker BJ, Meadows J, Rico DM, Vesely DL. The N-terminus and a 4, 000-MW peptide from the midportion of the N-terminus of the atrial natriuretic factor prohormone each circulate in humans and increase in congestive heart failure. Circulation 1989;80:438-49.
32. Vesely DL, Douglass MA, Dietz JR, Giordano AT, McCormick MT, Rodriguez-Paz G et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce a diuresis natriuresis and/or kaliuresis in humans. Circulation 1994;90:1129-40.
33. Vesely BA, McAfee Q, Gower WR Jr, Vesely DL. Four peptides decrease the number of human pancreatic adenocarcinoma cells. Eur J Clin Invest 2003;33:998-1005.
34. Vesely BA, Song S, Sanchez-Ramos J, Fitz SR, Solivan SM, Gower WR Jr. et al. Four peptide hormones decrease the number of human breast adenocarcinoma cells. Eur J Clin Invest 2005;35:60-9.